Mavenir to Present Go-Forward Corporate Strategy at Annual Global Analyst Event in Dallas 4-12-2024, 19:16

Physicians' Education Resource Announces 40th Annual Miami 9-02-2023, 00:30

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00